Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xenogenic anticancer vaccine
- Development stage
- Preclinical
- Lead developer
- Innovita Research
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Parenteral
01
Overview
The xenogenic anticancer vaccine is a preclinical-stage immunotherapy being developed by Innovita Research in collaboration with the National Cancer Institute, Lithuania. The vaccine is designed to overcome immune tolerance to self-antigens by utilizing xenogenic (cross-species) tumor-associated antigens (TAAs). By presenting antigens from a different species that are homologous to human TAAs, the vaccine aims to elicit a potent T-cell and B-cell mediated immune response against the patient's tumor cells. The program is currently being evaluated in preclinical murine models to establish proof-of-concept across various cancer indications.
- Other names
- Anticancer research vaccine
02
Targets
Hla (Staphylococcus aureus alpha toxin)PAP (Prostatic acid phosphatase)γδ TCR (T-cell receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on xenogenic anticancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xenogenic anticancer vaccine.